Tumor News and Research

RSS

Gefitinib just as effective as chemotherapy for lung cancer

Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of non-small cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease with far fewer side effects, according to an international Phase III clinical trial, led by researchers at The University of Texas M. D. Anderson Cancer Center.

20 Nov 2008

Bionovo to present phase 1B trial results of BZL101 in metastatic breast cancer

Bionovo, Inc. has announced the company will present results from the Phase 1B clinical trial of their lead drug candidate for advanced metastatic breast cancer, BZL101, at the Society for Integrative Oncology's Fifth International Conference in Atlanta, Georgia.

20 Nov 2008

Targeted nanoparticles boost platinum-based anticancer therapy

A research team from the Massachusetts Institute of Technology (MIT)-Harvard Center for Nanotechnology Excellence has custom-designed nanoparticles that can deliver the anticancer drug cisplatin specifically to prostate cancer cells.

20 Nov 2008

Nanoparticle reports on drug delivery to breast tumors, predicts response to therapy

One of the hallmarks of many nanoparticle-based anticancer therapeutics and imaging agents is that they accumulate in tumors thanks to the fact that they are small enough to escape from the bloodstream through the leaky blood vessels that surround tumors.

20 Nov 2008

Nanoparticle targets melanoma with siRNA

Research has shown that a particular receptor for the blood protein thrombin is overexpressed by highly metastatic melanoma cells.

20 Nov 2008

New compounds break up cancer-causing protein STAT3 and destroy breast cancer tumors.

Two new compounds created by a University of Central Florida professor show early promise for destroying breast cancer tumors.

19 Nov 2008

Survival of head and neck cancer patients is greatly affected by coexisting ailments

Current estimates for head and neck cancer survival are largely inaccurate because they widely disregard many of the most common diseases such patients have in addition to their primary cancer, says Jay Piccirillo, M.D., a head and neck specialist at Washington University School of Medicine in St. Louis, the Siteman Cancer Center and Barnes-Jewish Hospital.

19 Nov 2008

Soviet-developed immune formula boosts immune activity

A recent study on an American-made, Soviet-developed immune formula shows the product has a significant effect on immune function.

19 Nov 2008

REOLYSIN shown to benefit some sarcoma patients

New data shows that some sarcoma patients are benefiting from treatment with REOLYSIN, developed from a harmless virus called the reovirus that most people are exposed to at some point in their lives.

19 Nov 2008

Celator Pharmaceuticals enrols first patient in phase 2 study of CPX-351 in acute myeloid leukemia

Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).

19 Nov 2008

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

19 Nov 2008

New imaging technique tracks cancer-killing cells over prolonged period

Coaxing a patient's own cells to hunt down and tackle infected or diseased cells is a promising therapeutic approach for many disorders.

18 Nov 2008

Musculoskeletal Center wins $2.2 million to study biologics safety

The UAB Center for Education and Research on Therapeutics has won a $2.2 million federal grant to study the risks and benefits of a class of drugs called ‘biologics' -- genetically engineered agents targeting the immune system of patients with rheumatoid arthritis, Crohn's disease, psoriasis and other autoimmune disorders.

18 Nov 2008

ER/PR negative tumors associated with insurance status

African-American women are at a higher risk for ER/PR negative breast cancer.

18 Nov 2008

Discovery of 13 new tumor-suppressor genes in liver cancer

Over the years, hunting for cancer-related genes and understanding how they work has been an important, although time-consuming, exercise.

18 Nov 2008

Reduced-calories and exercise can modify a postmenopausal woman's risk of breast cancer

Scientists at the University of Texas at Austin have identified pathways by which a reduced-calorie diet and exercise can modify a postmenopausal woman's risk of breast cancer.

18 Nov 2008

Why only some former smokers develop lung cancer

Canadian researchers are trying to answer why some smokers develop lung cancer while others remain disease free, despite similar lifestyle changes.

17 Nov 2008

Palladin may play important role in metastasis of breast cancer cells

If scientists knew exactly what a breast cancer cell needs to spread, then they could stop the most deadly part of the disease: metastasis.

17 Nov 2008

Researchers find deadly protein that acts as a cancer master switch

Two critical properties of cancer cells are their ability to divide without restraint and to spread away from the primary tumor to establish new tumor sites.

17 Nov 2008

New molecular insight into vertebrate brain development

In the December 1st issue of G&D, Dr. Fred H. Gage (The Salk Institute for Biological Studies) and colleagues reveal a role for the Hippo signaling pathway in the regulation of vertebrate neural development, identifying new factors - and potential therapeutic targets - that may be involved in congenital brain size disorders and neurological tumor formation.

17 Nov 2008